Homeodomain interacting protein kinase 2 (HIPK2), the highly conserved nuclear serine/threonine kinase, is known to act as a co-repressor through interacting with a number of transcription factors. Notably, HIPK2 inhibits cell growth through the activation of p53. However, its *in vivo* function in insulin resistance is still unknown.

Recently, the discovery by Sjolund *et al*.[@b1] has implicated HIPK2 as a central modulator of adipogenesis. They found that deletion of HIPK2 in mice gave rise to decreased adipogenesis and increased insulin-sensitivity independence of the peroxisome proliferator-activated receptor gamma (PPARγ) signaling pathway. According to their result, we hypothesize that the expression of HIPK2 in the insulin-resistant population might be upregulated.

To testify our supposition, we analyzed the publicly available expression data from two human insulin-resistant expression data in GEO datasets that use the same platform. Contrary to our deduction, the HIPK2 gene was downregulated in the insulin-resistant population (Figure [1](#fig01){ref-type="fig"}a,b).

![Decreased expression of homeodomain interacting protein kinase 2 (HIPK2) in an insulin resistant population was associated with the peroxisome proliferator-activated receptor gamma (PPARγ) signaling pathway. (a,b) Expression of HIPK2 detected by gene expression microarray in panels of an insulin-resistant population using adipocytes (\*\*\**P* \< 0.001) compared with the corresponding control cells, as examined by unpaired two-sided Student\'s *t*-test. (c) The messenger ribonucleic acid (mRNA) levels of PPARγ, CCAAT/enhancer-binding protein alpha (CEBPA), CCAAT/enhancer-binding protein beta (CEBPB), fatty acid-binding protein 4 (FABP4), mesoderm specific transcript (MEST), cell death-inducing dFFA-like effector a (CIDEA), peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PPARGC1A) and uncoupling protein 1 (UCP1) in adipocytes of an insulin-resistant population (IR) in two GSE datasets (\**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001) compared with the corresponding controls (insulin sensitive \[IS\]). (d) The mRNA levels of PPARα, PPARδ, retinoid X receptor alpha (RXRA), fatty acid binding protein 1 (FABP1), nuclear receptor coactivator 4 (NCOA4), transducin (beta)-like 1X-linked (TBL1X) in the adipocytes of an insulin-resistant population in two GSE datasets (\**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001) compared with the corresponding controls. (e) The mRNA expression of HIPK2 in the presence of rosiglitazone (Rosi) or/and overexpressed PPARγ, detection was carried out 24 h after administration of Rosi with two replicates. Statistical significance was determined by paired two-tailed Student\'s *t*-test (\**P* \< 0.05). Data are presented as mean ± standard error of the mean, and was extracted from the Gene Expression Omnibus data repository (accession number: GSE13070, GSE20950 and GSE10192). DMSO, dimethylsulfoxide.](jdi0006-0594-f1){#fig01}

PPARγ is the key transcription factor in adipogenesis, as well as glucose and fatty acid metabolism, and alterations in the pathway lead to insulin resistance and type 2 diabetes mellitus[@b2]. According to the report by Sjolund *et al*.[@b1], the function of HIPK2 was not mediated by a PPARγ-dependent mechanism[@b1]. However, we identified that some downstream targets of PPARγ, which Sjolund *et al*. mentioned, were downregulated in adipocytes in insulin-resistant people, which is synchronously expressed with HIPK2 messenger ribonucleic acid expression (Figure [1](#fig01){ref-type="fig"}c). Some transcription cofactors of PPARγ shown by GeneMANIA (<http://www.genemania.org/>) were also downregulated in the adipocytes of the insulin-resistant population (Figure [1](#fig01){ref-type="fig"}d).

Rosiglitazone (Rosi), a member of the thiazolidinediones and an agonist of PPARγ, works as an insulin sensitizer in type 2 diabetes mellitus[@b3]. The present results showed that HIPK2 messenger ribonucleic acid expression was significantly increased in the presence of both Rosi and overexpressed PPARγ in murine marrow-derived U-33 cells, indicating a tendency of increased HIPK2 expression after administration of insulin sensitizer (Figure [1](#fig01){ref-type="fig"}e). In agreement with this, several other articles published the same results that HIPK2 expression was elevated after administration of insulin sensitizer, rosiglitazone and troglitazone ([Table S1](#SD1){ref-type="supplementary-material"}), suggested by The Comparative Toxicogenomics Database (<http://ctdbase.org/>).

Taken together, despite of Sjolund *et al*. discovery that HIPK2 deletion in mice induces increased insulin sensitivity and was not mediated by the PPARγ pathway, our data suggest that downexpression of HIPK2 was discovered in a population that suffered from decreased insulin sensitivity (insulin resistance) through the PPARγ-dependent pathway. This discrepancy might be caused by the following reasons: (i) metabolic differences between humans and murine; (ii) the discovery by Sjolund *et al*. was carried out on skeletal muscle, where the present results were shown in adipocytes; and (iii) our discovery was the result of a subset of humans, accordingly, the discovery by Sjolund *et al*. was based on a few HIPK2 knockout mice, the two studies all await further verification. Furthermore, we also showed that administration of insulin sensitizer could promote the elevated expression of HIPK2, thus providing a benefit for treatment of insulin resistance.

This work was supported by the National Natural Science Foundation of China (81471427).

Disclosure
==========

The authors declare no conflict of interest.

SUPPORTING INFORMATION
======================

Additional Supporting Information may be found in the online version of this article:

###### 

**Table S1** \| Insulin sensitizer induced homeodomain interacting protein kinase 2 (HIPK2) messenger ribonucleic acid expression.
